Small Cap Feast

Small Cap Feast – 02 September 2019

Dish of the Day:

No Joiners Today

Off the Menu:

No Leavers Today

What’s Cooking in the IPO Kitchen?


SEC S.p.A. Admission is following a reverse takeover under Rule 14 by SEC S.p.A of Porta Communications plc, another AIM quoted company. No funds being raised. Due 4 September. Mkt cap c £9.9m. The merger will create a business with global fee income of around €80m and a host of PR agencies, including Newgate, Publicasity and Newington.


Bracken Trading — The Group undertakes its main trade of lending as well as electricity generation through the operation of two solar farms. Admission on the 09/09/2019

Breakfast Buffet

Seeing Machines Ltd (SEE) 4.15p £135m

Seeing Machines Limited, the advanced computer vision technology company that designs AI-powered operator monitoring systems to improve transport safety, has been selected by a new Tier 1 supplier to deliver its FOVIO driver monitoring platform into a new generation architecture addressing additional car models for an existing European OEM customer.

Production for the additional car models is scheduled from 2022, with incremental revenue expected to exceed A$23m.

Seeing Machines’ FOVIO driver monitoring platform uses advanced machine vision technology to precisely measure and analyse head pose, eyelid movements and eye-gaze under a full spectrum of demanding lighting conditions, including through sunglasses. This data is processed to interpret driver attention state, focus, drowsiness and impairment levels to provide ADAS (advanced driver assistance systems) with critical inputs in real time.

Sirius Real Estate (SRE) 69.7p £1,421m

Sirius Real Estate, the leading operator of branded business parks providing conventional space and flexible workspace in Germany, announces that it has completed the acquisition of an office building adjacent to its Bochum Business Park, in Bochum, a city in the Ruhr region of Germany. The property was bought for a total consideration of 6.7 million including acquisition costs reflecting an EPRA net initial yield of 5.5%. The acquisition, notarised in July 2019, was settled in cash and funded using proceeds from recent asset recycling activity. The vendor was Häusser-Bau GmbH.

The property, constructed in 1970, provides 4,200 sqm of lettable space (81% office space, 15% storage and 4% service space) and 71 parking spaces on a total plot size of circa 3,300 sqm.  It is 100% let, producing an annual total income of circa €428,000 and annual net operating income of €370,000, reflecting a weighted average rent of €8.00 per/sqm with a remaining WALT of 2.2 years. The principal tenant is ThyssenKrupp Bilstein, a subsidiary of the giant ThyssenKrupp conglomerate which designs and manufactures shock absorbers.

21st Century Tech (C21) 3.1p £2.66m

21st Century Technology plc, the specialist provider of integrated IoT systems and software to the passenger transport markets, announced the award of contract for East Sussex County Council (“ESCC”) in a new framework agreement (the “Agreement”). The Agreement, for the supply, installation and support of real-time passenger information technology and content management software, is initially valued at approximately £0.5m, and work is due to commence in September 2019.

ESCC is working in partnership with Brighton & Hove City Council, West Sussex County Council and Surrey County Council to introduce a Content Management System (“CMS”). Together, they have chosen 21st Century’s new Electronic Passenger Information (“EPI”)’ software platform, to provide the foundations for their upgrade programme, which will also see 21st Century extend and refresh the passenger information display capabilities throughout the wider region.

Europa Metals Ltd (EUZ) 0.04p £5.81m

Europa Metals, the European focused lead, zinc and silver developer, announces that, further to the Company’s announcement of 15 August 2019, the ‘daughter hole’ (TOD-023D) has been successfully completed at its 100% owned Toral-lead-zinc-silver project located in the Province of León, northern Spain.


Drill hole TOD-023D has now been successfully completed.

The entire core sampled from the ‘daughter hole’ (TOD-023D) has been sent for independent metallurgical testwork and, accordingly, will not be assayed for updated JORC (2012) resource reporting purposes.

The metallurgical test results in due course are expected to advance the conceptual mine design at Toral and potentially provide a first determination of the concentrate products obtainable for potential future sale to smelter operations.

The parent hole (TOD-023) has been sampled and the samples sent for independent analysis to potentially inform a JORC (2012) resource update for the Toral Project.

Ashley House PLC (ASH) 4.75p £2.79m

Further to the Trading Update of 1st August, the Company advises that the Morgan Ashley scheme at Romsey has reached financial close. This is a 54 apartment extra care facility with a gross development value of £13.5m for the Registered Provider, Places for People Living + and Hampshire County Council. The scheme is one of the three schemes mentioned in previous updates that had been delayed. The Morgan Ashley team continues to work hard on the other two delayed schemes as well as other schemes which it looks to close over the coming months.

As previously advised, the delays have had an impact on the cash inflows to Ashley House and the Company is continuing to explore a number of sources of funding whilst managing its cash carefully. The Company will continue to update the market as appropriate.

Tekcapital plc (TEK) 8.07p £5m

Tekcapital Plc, the UK intellectual property (IP) investment group focused on creating marketplace value from investing in university technology, announced that there are now eleven companies testing MicroSalt®, a low sodium salt developed by the Group’s portfolio company Salarius for possible incorporation into their snack products.  Additionally, Salarius has received a registered trademark on SaltMe!® for its forthcoming full-flavour, low sodium snacks which it intends to launch in H1 2020.

To further accelerate commercial uptake and interest, Salarius will be attending two major food shows during the next 60 days; one of the biggest ingredients shows in the US: Supple Side West in Las Vegas and Natural Products Expo Eastin Baltimore.

C4X Discovery (C4XD) 39p £22.25m

C4X Discovery Holdings plc, a pioneering drug discovery company, today announces that Robin Carr, a renowned industry veteran who has worked at GSK and Astex, is to head up and form a C4XD Drug Discovery Advisory Network. 

The Advisory Network will bring together small molecule drug discovery and development experts from across the globe. It has been formed to harness industry expertise to build on C4XD’s drug discovery capabilities and attract valuable relationships that have the potential to advance its goal of becoming the world’s most productive drug discovery company. Robin and his team will act as ambassadors for C4XD within the Biotech and Pharmaceutical community, building awareness of C4XD’s technologies, capabilities and business.

Hurricane Energy PLC (HUR) 43p £870m

Hurricane Energy plc, the UK based oil and gas company focused on hydrocarbon resources in naturally fractured basement reservoirs, provides an operational update in relation to the Lancaster Early Production System (“Lancaster EPS”) and the 205/26b-14 well (“Lincoln Crestal”).


Lancaster EPS system availability and production since First Oil above guidance

Average production rate of c. 14,400 barrels of oil per day (“bopd”) from First Oil to latest lifting on 17 August

1.2 million barrels of crude oil sold to date

Lincoln Crestal well now being prepared for drill stem testing

AB Dynamics PLC (ABDP) 2,785p £611m

AB Dynamics, the designer, manufacturer and supplier of advanced testing systems and measurement products to the global automotive sector, announced that it has completed the acquisition of California based Dynamic Research Incorporated (“DRI”) for a maximum consideration of up to $24.7 million.

Faron Pharma. Oy (FARN) 106p £41.32m

Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, today announces that an abstract highlighting recent data from the Phase I/II MATINS study with Clevegen, its wholly-owned novel precision cancer immunotherapy, has been selected for a poster discussion presentation at the European Society of Medical Oncology (ESMO) 2019 Congress, taking place in Barcelona between 27 September and 1 October, 2019.

Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.